Eating disorders trial

Australia’s first trial of a best practice evidence-based approach to eating disorders treatment in a primary health network will be held on the Sunshine Coast.

The trial will provide primary and allied health professionals with access to training, knowledge, financial benefits and tertiary support. Outcomes of the project will influence future government policy on care pathways for people with eating disorders.

Types of treatment

The trial will improve access to:

  • Family based treatment (FBT)
  • Cognitive behavioural therapy – enhanced (CBT-E)
  • Treatment as specified in an individual psychiatric management plan
Eligibility

Participants must:

  • Live in the Sunshine Coast, Noosa or Gympie local government areas
  • Meet the criteria for an eating disorder (AN, BN, BED, OSFED) as defined in the DSM-5
  • Have no significant medical or psychiatric comorbidities that would affect treatment
  • Be assessed as having a low to moderate risk of suicide or self-harm; and

Priority will be given to people who:

  • Are in the early stages of developing an eating disorder (sub-clinical presentations or eating disorder diagnosis of less than 3 years duration)
  • Are seeking treatment for the first time, regardless of the duration of illness.
  • Are seeking assistance to manage the risks of relapse or recurrence after previous treatment for an eating disorder.

Help and support
For urgent support call Lifeline 13 11 14
Visit the Butterfly Foundation’s website
National Helpline on 1800 334 673
Email: support@thebutterflyfoundation.org.au

Trial dates

  • The trial is currently in the consultation and implementation phase.
  • A 3 year trial with a projected completion date, including evaluation of 30 May 2021.

Referral pathways

Participants will be referred for assessment and treatment by their own General Practitioner.

People who are receiving, or have received intensive treatment through a hospital, may be referred by their eating disorder specialist service for follow-up treatment and support.

Stay informed

Sign up to our newsletter to keep up to date about the trial.